Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
Sales | 57,677 | 48,756 | 52,913 | 52,304 | 56,036 |
Cost of Goods | 47,626 | 15,944 | 52,495 | 34,606 | 80,111 |
Gross Profit | 10,051 | 32,812 | 418 | 17,698 | -24,075 |
Operating Expenses | 76,016 | 88,642 | 80,254 | 83,240 | 62,823 |
Operating Income | -65,339 | -54,886 | -79,341 | -64,936 | -86,787 |
Interest Expense | 5,084 | 5,085 | 4,962 | 4,805 | 2,317 |
Other Income | 561 | 427 | 1,265 | 161 | 720 |
Pre-tax Income | -69,862 | -59,544 | -83,038 | -69,580 | -88,384 |
Net Income Continuous | -69,862 | -59,544 | -83,038 | -69,580 | -88,384 |
Net Income | $-69,862 | $-59,544 | $-83,038 | $-69,580 | $-88,384 |
EPS Basic Total Ops | -0.40 | -0.34 | -0.51 | -0.45 | -0.61 |
EPS Basic Continuous Ops | -0.39 | -0.34 | -0.51 | -0.45 | -0.60 |
EPS Diluted Total Ops | -0.40 | -0.34 | -0.51 | -0.45 | -0.61 |
EPS Diluted Continuous Ops | -0.39 | -0.34 | -0.51 | -0.45 | -0.60 |
EBITDA(a) | $-55,886 | $-45,402 | $-69,836 | $-55,423 | $-79,079 |